José Eulalio Samayoa

Generation Bio Reports Business Highlights and Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 3, 2022
Annual report, G&A, DNA, Research, Therapy, RES, Atlas, GLOBE, Form 10-K, José Eulalio Samayoa, D, Private Securities Litigation Reform Act, Generation, COVID-19, U.S. Securities and Exchange Commission, R, Atlas Venture, Liver, Security (finance), Vaccine

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and third quarter 2022 financial results.
  • Since co-founding Generation Bio in 2017, Dr. Samayoa has led strategy, corporate and portfolio development, most recently serving as senior vice president.
  • R&D Expenses:Research and development (R&D) expenses were$21.2millionfor the quarter ended September 30, 2022, compared to $22.0 million for the quarter ended September 30, 2021.
  • G&A Expenses:General and administrative (G&A) expenses were$11.5millionfor the quarter ended September 30, 2022, compared to $9.7 million for the quarter ended September 30, 2021.

Generation Bio Names Phillip Samayoa, Ph.D. Chief Strategy Officer

Retrieved on: 
Tuesday, September 20, 2022
Therapy, COVID-19, NSF, Biological engineering, MIT, Systems biology, University of California, San Diego, Form 10-K, U.S. Securities and Exchange Commission, Investment, Alector, Sanofi–Translate Bio COVID-19 vaccine, José Eulalio Samayoa, Atlas Venture, Physics, Tissue, RES, Private Securities Litigation Reform Act, Generation, UC, Â, Research, DNA, Security (finance), GLOBE, Annual report, Flagship Pioneering, Management, Vaccine, Pharmaceutical industry, Merck

CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced the promotion of Phillip Samayoa, Ph.D., to chief strategy officer.
  • Dr. Samayoa has led strategy, corporate and portfolio development at Generation Bio since he joined the company in 2017, most recently serving as senior vice president.
  • Phillip has been instrumental in building a holistic strategy for platform development that will enable its application to multiple genetic medicine modalities, said Geoff McDonough, M.D., president and chief executive officer of Generation Bio.
  • In this new role Phillip will lead corporate strategy, business development and discovery research, enabling the integration of these key strategic activities.